The findings indicated that PSME2 gene expression level may affect the prognosis and progression of GC patients, partly because of immune infiltration, and PSME2 may serve as a potential biomarker for GC patients, indicating a response to immunotherapy. This evidence concerns the gene PSME2 and gastric cancer.